CR20220250A - Métodos para el tratamiento de trastornos depresivos - Google Patents

Métodos para el tratamiento de trastornos depresivos

Info

Publication number
CR20220250A
CR20220250A CR20220250A CR20220250A CR20220250A CR 20220250 A CR20220250 A CR 20220250A CR 20220250 A CR20220250 A CR 20220250A CR 20220250 A CR20220250 A CR 20220250A CR 20220250 A CR20220250 A CR 20220250A
Authority
CR
Costa Rica
Prior art keywords
methods
depressive disorders
treatment
compound
present disclosure
Prior art date
Application number
CR20220250A
Other languages
English (en)
Inventor
Cynthia Louise Harden
Gregory N Beatch
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of CR20220250A publication Critical patent/CR20220250A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En determinadas modalidades, la presente descripción se refiere a métodos para tratar trastornos depresivos en humanos, en los que los métodos comprenden administrar por vía oral una cantidad terapéuticamente eficaz de <em>N</em>-[4-(6-fluoro-3,4-dihidro-1<em>H</em>-isoquinolin- 2-il)-2,6-dimetilfenil]-3,3-dimetilbutanamida (Compuesto A), para el ser humano que lo necesite. La presente descripción se refiere además a varios métodos mejorados de terapia y administración del Compuesto A.
CR20220250A 2019-11-08 2020-11-06 Métodos para el tratamiento de trastornos depresivos CR20220250A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962932724P 2019-11-08 2019-11-08
PCT/US2020/059481 WO2021092439A1 (en) 2019-11-08 2020-11-06 Methods of treating depressive disorders

Publications (1)

Publication Number Publication Date
CR20220250A true CR20220250A (es) 2022-08-19

Family

ID=73643360

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220250A CR20220250A (es) 2019-11-08 2020-11-06 Métodos para el tratamiento de trastornos depresivos

Country Status (19)

Country Link
US (2) US12178811B2 (es)
EP (1) EP4054580A1 (es)
JP (2) JP2022553569A (es)
KR (1) KR20220098746A (es)
CN (1) CN114667146A (es)
AU (1) AU2020380961A1 (es)
BR (1) BR112022008580A2 (es)
CA (1) CA3155812A1 (es)
CL (1) CL2022001102A1 (es)
CO (1) CO2022008001A2 (es)
CR (1) CR20220250A (es)
GE (2) GEP20257732B (es)
IL (1) IL292678A (es)
MA (1) MA56607A1 (es)
MX (1) MX2022005490A (es)
PE (1) PE20221766A1 (es)
PH (1) PH12022551110A1 (es)
TW (1) TW202128162A (es)
WO (1) WO2021092439A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021092439A1 (en) 2019-11-08 2021-05-14 Xenon Pharmaceuticals Inc. Methods of treating depressive disorders
CA3159876A1 (en) 2019-12-06 2021-06-10 James MURROUGH Method of treatment with kcnq channel openers
IL304920A (en) 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc A voltage-gated potassium channel opener for use in the treatment of anhedonia
CA3207002A1 (en) * 2021-02-09 2022-08-18 Jr James Philip Johnson Conjoint therapy for treating seizure disorders

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639385A (en) 1968-07-26 1972-02-01 Eastman Kodak Co Heterocyclic monoazo compounds from n n-diaralkyl anilines and polyester textile materials dyed therewith
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4181803A (en) 1973-12-14 1980-01-01 Eisai Co., Ltd. Propiophenone derivatives and preparation thereof
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
DE3337593A1 (de) 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
DE3369315D1 (en) 1982-10-27 1987-02-26 Degussa Derivatives of 2-amino-3-acylamino-6-benzylamino pyridine with an anti-epileptic activity
DE3665538D1 (en) 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
EP0193056B1 (de) 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
JP2583067B2 (ja) 1987-08-04 1997-02-19 住友化学工業株式会社 モノアゾ化合物およびそれを用いて疎水性繊維材料を染色または捺染する方法
GB8800199D0 (en) 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
MC2029A1 (fr) 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
US5629307A (en) 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US6004945A (en) 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
IN172468B (es) 1990-07-14 1993-08-14 Asta Medica Ag
US5643921A (en) 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5262419A (en) 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5428039A (en) 1994-02-20 1995-06-27 The Center For Innovative Technology Method for electively achieving reversible hyperpolarized cardiac arrest
JP4097285B2 (ja) 1994-09-22 2008-06-11 リチャード・アラン・スミス 種々の頑固な疾患の治療のための医薬の製造に有用な組成物
US5679706A (en) 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
EP2301562B1 (en) 1994-12-12 2013-04-17 Omeros Corporation Irrigation solution and method for inhibition of pain, inflammation and spasm
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
EP1004316B1 (en) 1997-08-08 2005-11-02 Chugai Seiyaku Kabushiki Kaisha Therapeutics for diabetic complications
US6265417B1 (en) 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
JP3441970B2 (ja) 1998-06-30 2003-09-02 株式会社サミー 豆腐の製造方法及び製造装置
JP2002542147A (ja) 1998-12-14 2002-12-10 セレジィ ファーマシューティカルス， インコーポレイテッド 肛門直腸障害の処置のための組成物および方法
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9903476D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
AU766648B2 (en) 1999-03-17 2003-10-23 Axys Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AT409083B (de) 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
EP1200073B1 (en) 1999-07-06 2007-01-10 Eli Lilly And Company SELECTIVE iGluR 5? RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
US6472165B1 (en) 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
NZ527771A (en) 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
NZ516610A (en) 1999-08-04 2004-05-28 Icagen Inc Benzanilides as potassium channel openers
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6383511B1 (en) 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
US6469042B1 (en) 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
AR033095A1 (es) 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
GB0121214D0 (en) 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
WO2003068769A1 (en) 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
WO2003097586A1 (en) 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
WO2003106454A1 (en) 2002-06-12 2003-12-24 Orchid Chemicals & Pharmaceuticals Ltd 1h-isoquinoline-oxazolidinone derivaties and their use as antibacterial agents
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
EP1581510A4 (en) 2002-11-22 2006-08-30 Bristol Myers Squibb Co 1-ARYL-2-HYDROXYETHYLAMIDEALS CALIUM CHANNEL OPENER
EP1585522B1 (en) 2002-12-23 2010-11-17 Icagen, Inc. Quinazolinones as potassium channel modulators
MXPA05006463A (es) 2002-12-27 2005-08-26 Lundbeck & Co As H Derivados de 1,2,4-triaminobenceno, utiles para tratar transtornos del sistema nervioso central.
WO2004080950A1 (en) 2003-03-14 2004-09-23 H. Lundbeck A/S Substituted aniline derivatives
BRPI0408437A (pt) 2003-03-21 2006-04-04 Lundbeck & Co As H derivados de p-diaminobenzeno substituìdos, composição farmacêutica, e, uso da mesma
EP1631546A1 (en) 2003-04-25 2006-03-08 H. Lundbeck A/S Sustituted indoline and indole derivatives
JP2006528231A (ja) 2003-05-27 2006-12-14 アルタナ　ファルマ　アクチエンゲゼルシャフト プロトンポンプ阻害剤と胃腸運動性を変更する化合物との医薬品組合せ物
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
US20050089473A1 (en) 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
ES2235626B1 (es) 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
KR20070030196A (ko) 2004-04-13 2007-03-15 이카겐, 인코포레이티드 칼륨 이온 채널 조절제로서의 폴리시클릭 피리딘
CA2565154A1 (en) 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
CA2589001A1 (en) 2004-11-19 2006-05-26 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for neuropathic pain
EP1688141A1 (en) 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
EP1861394A1 (en) 2005-03-03 2007-12-05 H.Lundbeck A/S Substituted pyridine derivatives
NZ563361A (en) 2005-06-02 2011-02-25 Schering Corp HCV protease inhibitors in combination with food
US7683058B2 (en) 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
EP2012769A1 (en) 2006-05-02 2009-01-14 Rundfeldt, Chris Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
BRPI0716715B1 (pt) * 2006-08-23 2021-07-06 Xenon Pharmaceuticals, Inc Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
CA2670966A1 (en) 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US20090018154A1 (en) 2007-05-17 2009-01-15 Endo Pharmaceuticals, Inc., A Corporation Of Delaware Opioid and methods of making and using the same
CN101790374A (zh) 2007-08-01 2010-07-28 H.隆德贝克有限公司 Kcnq钾通道开放剂用于减轻多巴胺能系统受到干扰的障碍或病症的症状或治疗这种障碍或病症的用途
WO2009074594A1 (en) * 2007-12-11 2009-06-18 Neurosearch A/S Novel 2-ethyl-methyl-amino-3-amido-6-amino-pyridine derivatives useful as potassium channel activators
US20100323016A1 (en) 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
EP2525788A2 (en) 2010-01-20 2012-11-28 Glaxo Group Limited Novel retigabine composition
WO2013067591A1 (en) 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
HRP20230808T1 (hr) * 2018-02-20 2023-11-10 H. Lundbeck A/S Derivati alkohola kao otvarači kv7 kalijevih kanala
FI3790548T3 (fi) 2018-05-11 2023-11-17 Xenon Pharmaceuticals Inc Menetelmiä jänniteriippuvaisen kaliumkanavan avaajan biosaatavuuden ja eksposition tehostamiseksi
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
WO2021092439A1 (en) 2019-11-08 2021-05-14 Xenon Pharmaceuticals Inc. Methods of treating depressive disorders
CA3159876A1 (en) 2019-12-06 2021-06-10 James MURROUGH Method of treatment with kcnq channel openers
US20210213009A1 (en) 2019-12-13 2021-07-15 Xenon Pharmaceuticals Inc. Methods of treating pain
IL304920A (en) 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc A voltage-gated potassium channel opener for use in the treatment of anhedonia
CA3207002A1 (en) 2021-02-09 2022-08-18 Jr James Philip Johnson Conjoint therapy for treating seizure disorders
EP4074696B1 (en) 2021-10-27 2026-02-04 Shanghai Zhimeng Biopharma, Inc. N-[4-(6-fluoro-3,4-dihydro-2(1h)-isoquinolinyl)-2,6-dimethylphenyl]-1-methyl-cyclopropane-acetamide, a potassium channel regulator for the treatment of epilepsy

Also Published As

Publication number Publication date
CN114667146A (zh) 2022-06-24
PE20221766A1 (es) 2022-11-11
US20210161886A1 (en) 2021-06-03
IL292678A (en) 2022-07-01
JP2022553569A (ja) 2022-12-23
GEAP202415942A (en) 2024-10-28
NZ787838A (en) 2025-08-29
CA3155812A1 (en) 2021-05-14
MA56607A1 (fr) 2022-10-31
KR20220098746A (ko) 2022-07-12
GEP20257732B (en) 2025-02-10
US20250108044A1 (en) 2025-04-03
TW202128162A (zh) 2021-08-01
JP2026001049A (ja) 2026-01-06
WO2021092439A1 (en) 2021-05-14
PH12022551110A1 (en) 2024-02-26
EP4054580A1 (en) 2022-09-14
BR112022008580A2 (pt) 2022-08-09
MX2022005490A (es) 2022-08-10
CL2022001102A1 (es) 2023-01-27
US12178811B2 (en) 2024-12-31
AU2020380961A1 (en) 2022-05-26
CO2022008001A2 (es) 2022-06-10

Similar Documents

Publication Publication Date Title
CR20220250A (es) Métodos para el tratamiento de trastornos depresivos
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
MX2020012008A (es) Métodos para potenciar la biodisponibilidad y la exposición de un abridor de canales de potasio dependientes de voltaje.
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
CL2022002566A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572)
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
CO2022008606A2 (es) Derivados de piridopirimidinona como antagonistas de ahr
MX2023003942A (es) Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r.
MX2023009314A (es) Apertura del canal de potasio dependiente de voltaje para usarse en el tratamiento de la anhedonia.
CO2021005797A2 (es) Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia
CL2022000781A1 (es) Tratamientos cognitivos medicinales
CL2022001477A1 (es) Uso de un abridor de canal de potasio kv7 para tratar el dolor
MX2019002047A (es) Metodos y composiciones para tratar infecciones fungicas cutaneas.
MX2015013115A (es) Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue.
PY1944026A (es) Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
MX2022000082A (es) Composiciones terapeuticas y metodos para tratar canceres.
CO2023011948A2 (es) Terapia conjunta para el tratamiento de trastornos convulsivos
MX2021013000A (es) Regimenes terapeuticos de combinacion con 1,6-dibromo-1,6-dideoxy- dulcitol.
AR122344A1 (es) Uso de reboxetina para tratar desórdenes del sistema nervioso
CL2022001476A1 (es) Uso de reboxetina para tratar los trastornos del sistema nervioso
PE20230181A1 (es) Uso de reboxetina para tratar los trastornos del sistema nervioso
CO2021011328A2 (es) Derivados de 2h-indazol como agentes terapéuticos para cánceres cerebrales y metástasis cerebrales